-+ 0.00%
-+ 0.00%
-+ 0.00%

Vir Biotechnology's Hepatitis Delta Therapy Meets Primary Endpoint in Phase 3 Trial

PUBT·11/08/2026 21:15:29
Listen to the news
Vir Biotechnology's Hepatitis Delta Therapy Meets Primary Endpoint in Phase 3 Trial
  • Vir Biotechnology's elebsiran-tobevibart combination met the primary endpoint in the pivotal Phase 3 ECLIPSE 1 trial for chronic hepatitis delta.
  • Monthly treatment achieved undetectable virus with normalized liver enzymes; the regimen was well tolerated, with no treatment interruptions or discontinuations.
  • Results were presented at the American Association for the Study of Liver Diseases' The Liver Meeting 2026 in Denver.
  • Additional pivotal trial results are expected in the first quarter of 2027, supporting a planned FDA submission in mid-2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261108631000) on November 08, 2026, and is solely responsible for the information contained therein.